CS
VIR icon

Credit Suisse’s Vir Biotechnology VIR Stock Holding History

Credit Suisse’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1.02M Sell
100,443
-27,329
-21% -$278K ﹤0.01% 2257
2023
Q4 		$1.29M Sell
127,772
-49,421
-28% -$452K ﹤0.01% 2173
2023
Q3 		$1.66M Buy
177,193
+32,425
+22% +$462K ﹤0.01% 1946
2023
Q2 		$3.55M Sell
144,768
-24,204
-14% -$608K ﹤0.01% 1559
2023
Q1 		$3.93M Buy
168,972
+43,034
+34% +$1.1M ﹤0.01% 1467
2022
Q4 		$3.19M Buy
125,938
+38,740
+44% +$950K ﹤0.01% 1606
2022
Q3 		$1.68M Buy
87,198
+25,262
+41% +$642K ﹤0.01% 1957
2022
Q2 		$1.58M Buy
61,936
+8,409
+16% +$196K ﹤0.01% 2075
2022
Q1 		$1.38M Sell
53,527
-3,630
-6% -$108K ﹤0.01% 2326
2021
Q4 		$2.39M Buy
57,157
+5,835
+11% +$229K ﹤0.01% 2655
2021
Q3 		$2.23M Sell
51,322
-6,851
-12% -$297K ﹤0.01% 2737
2021
Q2 		$2.75M Buy
58,173
+47,600
+450% +$2.16M ﹤0.01% 2594
2021
Q1 		$542K Sell
10,573
-51,263
-83% -$2.76M ﹤0.01% 3713
2020
Q4 		$1.66M Buy
+61,836
New +$2.01M ﹤0.01% 2963
2020
Q3 		– Sell
-5,804
Closed -$238K – 4139
2020
Q2 		$238K Sell
5,804
-2,506
-30% -$84.1K ﹤0.01% 3677
2020
Q1 		$285K Buy
+8,310
New +$223K ﹤0.01% 3455

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Credit Suisse's VIR Position: Q1 2024 in Review

Credit Suisse reduced its Vir Biotechnology (VIR) stake by 21% in Q1 2024, selling an estimated $278K and leaving 100,443 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #2257.

Credit Suisse first reported a position in VIR in Q1 2020 and has held it in 16 quarters since. The position peaked at $3.93M in Q1 2023. 209 funds tracked by Wall St. Rank hold VIR as of Q1 2024.

  • Credit Suisse held 100,443 shares of Vir Biotechnology worth $1.02M as of Q1 2024.
  • Credit Suisse sold 27,329 Vir Biotechnology shares in Q1 2024, an estimated $278K.
  • Vir Biotechnology made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2257 holding.
  • Credit Suisse first reported a position in Vir Biotechnology in Q1 2020 and has held it in 16 quarters since.
  • Credit Suisse's Vir Biotechnology position peaked at $3.93M in Q1 2023.
  • 209 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.